Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Evoke Pharma, Inc. ( NASDAQ: EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Daniel Kontoh-Boateng – DKB Partners Matt D’Onofrio – Chief Executive Officer Chris Quesenberry – Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback